Claris Ventures makes equity investments in early stage biopharma companies with a clear vision and solid scientific evidence. The company provides capital, competence and hands-on support to jump start clinical development programs and pursue value creation based on clinical evidence.

Claris Ventures

Claris Ventures SGR SpA makes equity investments in early stage biopharma companies with a clear vision and solid scientific evidence.
We are fascinated by science and we are committed to help the best innovators in addressing strong unmet clinical needs, spanning from rare diseases to oncology, immunology and other life threatening disease areas. 
We provide capital, competence and hands-on support to jump start clinical development programs and pursue value creation based on clinical evidence.

Claris Biotech I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing” (or the relevant translation).

🧪 FENS Forum 2024 was incredible! 

Hundreds of speakers and thousands of participants from around the world gathered in #Vienna to share breakthrough advancements in CNS research 🧠

It was an amazing opportunity to explore emerging trends in neuroscience, be surrounded by top researchers, and connect with some of our founders! 

#FENS2024 #Biotech #Neuroscience #venturecapital

🌟 Exciting News Alert! 🌟

We're thrilled to share the groundbreaking partnership between one of our portfolio companies, Sibylla Biotech , and The University of Texas MD Anderson Cancer Center. Together, they're embarking on a pioneering journey to develop novel small-molecule cancer therapies known as Folding Interfering Degraders (FIDs).

#CancerResearch #Partnership #Sibylla #MDAnderson #FoldTheFuture

🔬🌱 Exciting times at the Ugly Duck 2023, the European Investment Fund event with more than 300 Partners from venture capital funds across Europe! 🚀

As a Biotech-focused VC fund, we're at the forefront of innovation, and it's inspiring to come together to discuss the future of biotech, sustainability, and more.

Our discussions will revolve around innovation, nurturing human capital, closing the gender gap, and ensuring a sustainable future for all. 🌍💡

Life Science continues to be a strategic sector with consistent returns 🌟

Half of top performing funds are managed by new teams 

Let's embark on this journey together and make a lasting impact on the world! 👩‍🔬👨‍💼

 #EIF #UglyDuck2023 #VentureCapital #BiotechInnovation  #DiversityInTech

📢 We could not wish for a better start of 2024, with our portfolio company Resalis Therapeutics announcing a €10m financing round led by Sunstone Life Science Ventures, together with us and other previous investors including IAG and Club degli Investitori! 

Having led the very first financing in 2021, that allowed the company to conduct preclinical studies and be soon ready to move into clinical development, at Claris Ventures we are honored to have new experienced investors joining the syndicate - welcome Claus Andersson! ✌ 

Congratulations to Alessandro Toniolo, Sakari Kauppinen, Riccardo Panella and the whole team for the amazing work done so far, able to establish a unique positioning opportunity for our candidate RES-010 into the #obesity space, at the right moment.  

Onward and upward 🚀 

For more information read the full announcement here: https://lnkd.in/dVCueQKr

#biotech #vc #venturecapital #innovation #italy

📣 The pharmaceutical company Bristol Myers Squibb (NYSE: MBY) just announced its investment in our portfolio company NeoPhore Ltd - and we couldn't be happier!

💊 NeoPhore unique approach could offer therapeutic opportunities to patients suffering from solid cancers not eligible to immune check-point inhibitors, a possible paradigm shift in immune-oncology. Bristol Myers Squibb investment is a testament to the relevance and uniqueness of NeoPhore science, originated from Prof. Alberto Bardelli's lab. 

Kudos to the whole team, upwards and onwards!

#biotech #venturecapital #pharma #investmnet #deal

🎉Welcome Chiara Donini, PhD to Claris Ventures!🎉

We are thrilled to announce Chiara as our new Senior Analyst! 🌟

Chiara brings over 5 years of post-doctoral experience in immuno-oncology and cell therapy. She holds a PhD in Complex Systems for Life Sciences from the University of Turin and advanced studies in Pharma Management from Alma Laboris Business School.

Her roles have included developing CAR-cell therapy strategies at San Luigi Gonzaga Hospital and working in technology transfer at Bioindustry Park Silvano Fumero.

Chiara's expertise and proactive approach make her a valuable addition to our team. Join us in welcoming her to Claris Ventures! 

#Welcome #ClarisVentures #LifeSciences #Biotechnology #NewTeamMember #VentureCapital

Metric
Company Name	Claris Ventures
Symbol
MSH ID	COM:CLARISVENTURES
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital in Biotechnology and Healthcare
Country	IT
Stage
Employee Count	10
Website	clarisventures.com
LinkedIn	clarisventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CLARISVENTURES

Claris Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue